Navigation Links
More doctors use ultrasound to diagnose, manage rheumatic diseases
Date:10/28/2012

More rheumatologists are embracing musculoskeletal ultrasound (MSUS) to diagnose and manage rheumatic diseases. In response, the American College of Rheumatology (ACR) assembled a task force to investigate and determine best practices for use of MSUS in rheumatology practice. The resulting scenario-based recommendations, which aim to help clinicians understand when it is reasonable to integrate MSUS into their rheumatology practices, now appear online in Arthritis Care & Research.

In Europe, more than 100 million individuals are affected by rheumatic diseases, according to the European League Against Rheumatism (EULAR). The ACR estimates that nearly 50 million Americans are burdened by arthritis and more than 7 million individuals suffer from inflammatory rheumatic diseases such as systemic lupus erythematosus, rheumatoid arthritis and gout.

"With so many people affected by rheumatic diseases, including arthritis, a diagnostic tool such as MSUS that is minimally invasive and with little risk to patients is an important tool for rheumatologists," explains lead researcher Dr. Tim McAlindon from Tufts Medical Center in Boston, Mass. "Our task force goal was to establish when use of MSUS was 'reasonable' in a number of medical situations."

The task force reviewed medical literature to come up with scenario-based recommendations for how MSUS could be used in rheumatology practice. These recommendations include a rating by type of evidence, with Level A supported by at least two randomized clinical trials or one or more meta-analyses of randomized trials; Level B backed by one randomized trial, non-randomized studies or meta-analyses of non-randomized studies; and Level C confirmed by consensus expert opinion, case studies, or standard clinical care.

The complete list of 14 recommendations of the reasonable use of MSUS in rheumatology, along with level of evidence, is published in the article. Partial list of recommendations includes:

  • For a patient with articular pain, swelling or mechanical symptoms, without definitive diagnosis on clinical exam, it is reasonable to use MSUS to further elucidate the diagnosis at the following joints: glenohumeral, acromioclavicular, sternoclavicular, elbow, wrist, metacarpophalangeal, interphalangeal, hip, knee, ankle, midfoot and metatarsophalangeal. Level of evidence: B.
  • For a patient with diagnosed inflammatory arthritis and new or ongoing symptoms without definitive diagnosis on clinical exam, it is reasonable to use MSUS to evaluate for inflammatory disease activity, structural damage or emergence of an alternate cause at the following sites: glenohumeral, acromioclavicular, elbow, wrist, metacarpophalangeal, interphalangeal, hip, knee, ankle, midfoot and metatarsophalangeal, and entheseal. Level B.
  • For a patient with shoulder pain or mechanical symptoms, without definitive diagnosis on clinical exam, it is reasonable to use MSUS to evaluate underlying structural disorders; but not for adhesive capsulitis or as preparation for surgical intervention. Level B.
  • It is reasonable to use MSUS to evaluate the parotid and submandibular glands in a patient being evaluated for Sjgren's disease to determine whether they have typical changes as further evidence of the disorder. Level B.
  • For a patient with symptoms in the region of a joint whose evaluation is obfuscated by adipose or other local derangements of soft tissue, it is reasonable to use MSUS to facilitate clinical assessment at the glenohumeral, acromioclavicular, elbow, wrist, hand, metacarpophalangeal, interphalangeal, hip, knee, ankle/foot, and metatarsophalangeal joints. Level C.
  • For a patient with regional neuropathic pain without definitive diagnosis on clinical exam, it is reasonable to use MSUS to diagnose entrapment of the median nerve at the carpal tunnel; ulnar nerve at the cubital tunnel; and posterior tibial nerve at the tarsal tunnel. Level B.
  • It is reasonable to use MSUS to guide articular and peri-articular aspiration or injection at sites that include the synovial, tenosynovial, bursal, peritendinous and perientheseal areas. Level A.

The benefits of MSUS use include a faster, more accurate diagnosis, better measurement of treatment success, reduced procedural pain, and improved patient satisfaction. However, the authors highlight that economic impact was not part of this study. Dr. McAlindon concludes, "Further study of the cost-effectiveness and long-term outcomes of MSUS is necessary to determine its value compared to other interventions."


'/>"/>

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related medicine news :

1. Informatics approach helps doctors, patients make sense of genome data
2. Doctors Biased Against Drug Company Research, Study Finds
3. Cancer Survivors Prefer to Stay With Cancer Doctors: Study
4. Doctors who perform abortions are compelled by conscience, just like those who refuse
5. Few Doctors Discuss Exercise With Cancer Patients: Study
6. Worlds largest meeting of ear, nose, and throat doctors
7. Doctors Who Self-Refer to Radiation Clinics Add to Patients Burden: Study
8. Many U.S. Doctors Have Symptoms of Burnout: Survey
9. With Very Sick Infants, Doctors and Parents Often Miscommunicate
10. Nurses as effective as doctors in treatment of HIV patients
11. Doctors can now detect hard-to-diagnose prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ... Care Association™ (ALCA) to conduct a survey that takes a closer look at cases ... illustrates the prevalence and causes of TBI among the aging population, and identifies the ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors ... the latest addition to its growing list of Partner Firms. S.S. Nesbitt ... from Orlando to Huntsville and in between. , Harnessing the experience and insights ...
(Date:2/10/2016)... FL (PRWEB) , ... February 10, 2016 , ... AxoGen, ... market, will report results for the fourth quarter and full year ended December 31, ... host a conference call and webcast for the investment community following the release at ...
(Date:2/10/2016)... ... , ... AHRA: The Association for Medical Imaging Management announced ... serve as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, Lead ... communicate with their own organizational staff and leadership. , “I am so ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 ... "Better with Age: The Ultimate Guide to Brain Training" by award-winning author Phyllis ... book’s publication date is March 16, 2016. A free review copy is available ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 9, 2016 On Tuesday, February ... met with its Arthritis Advisory Committee to ... Johnson & Johnson,s Remicade and most likely ... the U.S. The Biologics Prescribers Collaborative (BPC) ... Alliance for Patient Access, American Association of ...
(Date:2/10/2016)... LONDON , February 10, 2016 ... window and M 1 receptor selectivity   ... Heptares StaR® technology, which has entered clinical development ... patients with dementia and schizophrenia.   --> ... StaR® technology, which has entered clinical development as ...
(Date:2/9/2016)... BILLERICA, Mass. , Feb. 9, 2016  Insulet Corporation ... in tubeless insulin pump technology with its OmniPod ... David A. Lemoine has been appointed to Insulet,s ... comprised of nine directors, eight of whom are independent. ... over 40 years of audit and finance experience and a ...
Breaking Medicine Technology: